Onconetix, Inc. (NASDAQ:ONCO) Short Interest Down 37.4% in August

Posted by Matthew Steigler on Sep 17th, 2024

Onconetix, Inc. (NASDAQ:ONCO – Get Free Report) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 695,100 shares, a decline of 37.4% from the August 15th total of 1,110,000 shares. Currently, 2.5% of the company’s shares are sold short. Based on an average trading volume of 10,050,000 shares, the short-interest ratio is currently 0.1 days.

Institutional Investors Weigh In On Onconetix

A hedge fund recently bought a new stake in Onconetix stock. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Onconetix, Inc. (NASDAQ:ONCO – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 306,079 shares of the company’s stock, valued at approximately $51,000. Zurcher Kantonalbank Zurich Cantonalbank owned about 1.37% of Onconetix as of its most recent filing with the SEC. Hedge funds and other institutional investors own 23.89% of the company’s stock.

Onconetix Price Performance

Shares of Onconetix stock remained flat at $0.12 during trading hours on Monday. The company’s stock had a trading volume of 508,477 shares, compared to its average volume of 6,352,594. The company has a debt-to-equity ratio of 0.08, a current ratio of 0.10 and a quick ratio of 0.09. The stock has a 50 day simple moving average of $0.15 and a 200 day simple moving average of $0.15. Onconetix has a 12 month low of $0.10 and a 12 month high of $0.68.

Onconetix (NASDAQ:ONCO – Get Free Report) last posted its earnings results on Thursday, August 29th. The company reported ($0.23) earnings per share (EPS) for the quarter. The company had revenue of $0.71 million during the quarter.

Onconetix Company Profile

(Get Free Report)

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.